Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.81 USD
Change Today +0.10 / 0.93%
Volume 1.2M
RPTP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (RPTP) Snapshot

Open
$10.74
Previous Close
$10.71
Day High
$11.06
Day Low
$10.52
52 Week High
07/2/14 - $12.20
52 Week Low
05/9/14 - $7.12
Market Cap
847.1M
Average Volume 10 Days
800.2K
EPS TTM
$-0.83
Shares Outstanding
78.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RAPTOR PHARMACEUTICAL CORP (RPTP)

raptor pharmaceutical corp (RPTP) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (RPTP) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (RPTP) Details

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs include RP103 that is used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidates comprise Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical product candidates include cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

123 Employees
Last Reported Date: 03/2/15
Founded in 2005

raptor pharmaceutical corp (RPTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $421.1K
Chief Business Officer
Total Annual Compensation: $305.9K
Chief Commercial Officer
Total Annual Compensation: $114.9K
Corporate Controller
Total Annual Compensation: $210.8K
Compensation as of Fiscal Year 2014.

raptor pharmaceutical corp (RPTP) Key Developments

Raptor Pharmaceuticals Seeks Acquisitions

Raptor Pharmaceuticals Corp. (NasdaqGM:RPTP) intends to use the net proceeds from the offering to fund their commercial efforts, their clinical and preclinical development programs and other general corporate purposes. They may also use a portion of the net proceeds from this offering for product portfolio expansion opportunities, which may include the acquisition or licensing of other products, businesses or technologies, although they have no present commitments or agreements to do so.

Raptor Pharmaceutical Corp. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Raptor Pharmaceutical Corp. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net product sales were $17,286,000 against $10,248,000 a year ago. Loss from operations was $15,941,000 against $10,669,000 a year ago. Net loss before provision for income taxes was $18,872,000 against $12,091,000 a year ago. Net loss was $18,923,000 or $0.29 basic and diluted per share against $12,091,000 or $0.20 basic and diluted per share a year ago. Non-GAAP loss was $16,125,000 or $0.25 basic and diluted per share against $10,481,000 or $0.17 basic and diluted per share a year ago. The fourth quarter of 2014 was another exciting period of significant progress for the company, from a commercial, development and organizational perspective. For the year, the company reported net product sales were $69,497,000 against $16,872,000 a year ago. Loss from operations was $40,050,000 against $51,906,000 a year ago. Net loss before provision for income taxes was $52,486,000 against $69,417,000 a year ago. Net loss was $52,540,000 or $0.83 basic and diluted per share against $69,417,000 or $1.20 basic and diluted per share a year ago. Non-GAAP loss was $40,494,000 or $0.64 basic and diluted per share against $62,387,000 or $1.08 basic and diluted per share a year ago. The full year of 2014 was another exciting period of significant progress for the company, from a commercial, development and organizational perspective. The company is establishing 2015 financial guidance with global net product sales for PROCYSBI between $80 and $90 million and non-GAAP operating expense, excluding non-cash stock-based compensation expense, between $115 and $125 million.

Raptor Pharmaceuticals Mulls Acquisitions

Raptor Pharmaceuticals Corp. (NasdaqGM:RPTP) is seeking acquisitions. Julie Anne Smith, President and Chief Operating Officer of Raptor Pharmaceuticals, said in Raptor Pharmaceuticals earnings call, “We remain committed to our strategy of enabling the growth and diversification of our [sustaining] franchise into new indications, and we are intensifying our efforts to identify potentially new compounds from both our internal discovery program as well as through prudent acquisition. And now I will turn the call over to Mike.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPTP:US $10.81 USD +0.10

RPTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $42.49 USD -0.13
Illumina Inc $189.59 USD -3.01
View Industry Companies
 

Industry Analysis

RPTP

Industry Average

Valuation RPTP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit www.raptorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.